Marinus Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
Marinus Pharmaceuticals Il CEO è Scott Braunstein, nominato in Aug2019, e ha un mandato di 5.25 anni. la retribuzione annua totale è $ 3.21M, composta da 20.2% di stipendio e 79.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.22% delle azioni della società, per un valore di $ 36.63K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4 anni e 4.6 anni.
Informazioni chiave
Scott Braunstein
Amministratore delegato
US$3.2m
Compenso totale
| Percentuale dello stipendio del CEO | 20.2% |
| Mandato del CEO | 5.3yrs |
| Proprietà del CEO | 0.2% |
| Durata media del management | 4yrs |
| Durata media del Consiglio di amministrazione | 4.6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price
Sep 20
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%
Apr 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$140m |
| Jun 30 2024 | n/a | n/a | -US$149m |
| Mar 31 2024 | n/a | n/a | -US$145m |
| Dec 31 2023 | US$3m | US$650k | -US$141m |
| Sep 30 2023 | n/a | n/a | -US$134m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | US$3m | US$591k | -US$20m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$105m |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$4m | US$574k | -US$99m |
| Sep 30 2021 | n/a | n/a | -US$88m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$76m |
| Dec 31 2020 | US$4m | US$556k | -US$76m |
| Sep 30 2020 | n/a | n/a | -US$74m |
| Jun 30 2020 | n/a | n/a | -US$72m |
| Mar 31 2020 | n/a | n/a | -US$69m |
| Dec 31 2019 | US$2m | US$305k | -US$54m |
| Sep 30 2019 | n/a | n/a | -US$49m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$43m |
| Dec 31 2018 | US$210k | n/a | -US$37m |
Compensazione vs Mercato: La retribuzione totale di Scott ($USD 3.21M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 651.15K ).
Compensazione vs guadagni: La retribuzione di Scott è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Scott Braunstein (61 yo)
5.3yrs
Mandato
US$3,214,100
Compensazione
Dr. Scott N. Braunstein, M.D., has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He serves as an Independent Director at Caribou Biosciences, Inc. since June 2021. He...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Chairman | 5.3yrs | US$3.21m | 0.22% $ 36.6k | |
| COO, CFO & Treasurer | 3.6yrs | US$1.44m | 0.031% $ 5.3k | |
| Chief Medical Officer | 5.1yrs | US$1.37m | 0.031% $ 5.3k | |
| Chief Scientific Officer | no data | Nessun dato | Nessun dato | |
| Senior VP of Investor Relations | 1.4yrs | Nessun dato | Nessun dato | |
| Senior VP | 4.4yrs | Nessun dato | 0.022% $ 3.7k | |
| Director of Corporate Communications & Investor Relations | 1.4yrs | Nessun dato | Nessun dato | |
| Chief Regulatory & Quality Assurance Officer | no data | Nessun dato | Nessun dato | |
| Chief Commercial Officer | 4yrs | Nessun dato | 0.034% $ 5.8k | |
| Chief Chemistry | no data | Nessun dato | Nessun dato |
4.0yrs
Durata media
61yo
Età media
Gestione esperta: Il team dirigenziale di MRNS è considerato esperto (durata media dell'incarico 4 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Chairman | 6.2yrs | US$3.21m | 0.22% $ 36.6k | |
| Lead Independent Director | 15.9yrs | US$202.52k | 0.025% $ 4.3k | |
| Independent Director | 4.9yrs | US$162.52k | 0.010% $ 1.7k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 8.2yrs | US$160.02k | 0.011% $ 1.9k | |
| Independent Director | 3.7yrs | US$154.74k | 0.012% $ 2.0k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 4.3yrs | US$157.52k | 0.0096% $ 1.6k | |
| Independent Director | 1.8yrs | US$249.21k | Nessun dato | |
| Independent Director | 1.6yrs | US$304.81k | 0.0044% $ 738.5 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato |
4.6yrs
Durata media
61.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MRNS sono considerati esperti (durata media dell'incarico 4.6 anni).